Jasper Therapeutics, Inc. - Class A Common Stock JSPR 深 沪
等待开盘 10-16 09:30:00 美东时间
2.60
+0.090
+3.59%
华盛通- 最 高2.61
- 今 开2.50
- 成交量 48.04万股
- 最 低 2.45
- 昨 收 2.51
- 总市值 4225.86万
- 52周最高 26.05
- 市盈率 静 --
- 换手率 2.96%
- 52周最低 2.215
- 委 比 -99.94%
- 总股本 1625.33万
- 历史最高 188.80
- 量 比 1.33
- 振 幅 6.37%
- 历史最低 2.215
- 每 手 1
- 风险率 7.23%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Jasper To Contact Him Directly To Discuss Their Options If you purchased or...
10-11 08:05
美股大行评级 | 潜在涨幅1650.0%！Ascendiant Capital维持GRI Bio"买入"评级，目标价上调至35美元
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从34美元升至35美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.5美元升至7.75美元
09-23 09:52
Jasper Therapeutics prices $30M equity offering
Jasper Therapeutics (NASDAQ:JSPR) priced an underwritten public offering of about 11.7 million shares and accompanying warrants at $2.43 each, plus 675,000 pre-funded warrants at the same price minus ...
09-19 15:53
Jasper Therapeutics Announces Proposed Underwritten Public Offering Of Its Common Stock; No Financial Terms Disclosed
Jasper Therapeutics, Inc. (NASDAQ:JSPR) ("Jasper"), a clinical-stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell driven diseases such
09-19 04:11
Jasper Therapeutics Announces Proposed Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants
Jasper Therapeutics announced plans for an underwritten public offering of its common stock or pre-funded warrants, with proceeds aimed at advancing its briquilimab development for mast cell-driven diseases like chronic urticaria and asthma. TD Cowen is the sole book-running manager, and the offering is subject to market conditions. Briquilimab targets KIT receptor, reducing mast cell survival and inflammatory responses. Jasper expects to use fun...
09-18 20:08
Jasper Therapeutics to Present at Upcoming Investor Conferences
Jasper Therapeutics, a biotechnology company developing briquilimab for mast cell-driven diseases like chronic urticaria and asthma, announced its participation in two upcoming investor conferences in September 2025. The Cantor Fitzgerald Global Healthcare Conference will host a fireside chat on September 3, 2025, while the H.C. Wainwright Global Investment Conference will feature another on September 9, 2025. Briquilimab targets KIT to deplete m...
08-27 20:30
UBS Maintains Buy on Jasper Therapeutics, Lowers Price Target to $25
UBS analyst Trung Huynh maintains Jasper Therapeutics (NASDAQ:JSPR) with a Buy and lowers the price target from $29 to $25.
08-15 22:21
Jasper Therapeutics Q2 EPS $(1.74) Misses $(1.40) Estimate
Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(1.74) per share which missed the analyst consensus estimate of $(1.40) by 24.55 percent. This is a 79.38 percent decrease over losses of $(0.97) per share
08-14 04:26
Jasper Therapeutics Announces Major Corporate Reorganization
Jasper Therapeutics ( ($JSPR) ) has provided an update. On July 8, 2025, Jasper...
07-09 20:29
Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway
Jasper Therapeutics announced a corporate reorganization to extend its cash runway, including a workforce reduction of approximately 50%. Dr. Edwin Tucker is departing as Chief Medical Officer, and Dr. Daniel Adelman will serve as Acting Chief Medical Officer. The company is focusing on its briquilimab programs in chronic urticaria and halting other clinical and preclinical programs.
07-09 12:00
